Acumen Pharmaceuticals, Inc. (ABOS) — Stock Score Summary

Acumen Pharmaceuticals, Inc. (ABOS) has a MoatMap StockRank of 27/100 based on Quality (22/100), Value (38/100), and Momentum (54/100) factor scores. The current signal is SELL. Acumen Pharmaceuticals is a clinical-stage biotech developing Alzheimer's treatments. It is pre-revenue, highly speculative, and carries binary clinical trial risks, violating our core quality compounder criteria.

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for neurodegenerative diseases, particularly Alzheimer's disease. The company concentrates on a highly specific target (amyloid-beta oligomers) with its lead candidate, ACU90, aiming to address the underlying pathology of Alzheimer's. Acumen Pharmaceuticals is a focused biopharmaceutical firm in the high-risk, high-reward Alzheimer's therapeutic space, pursuing innovative disease modification approaches.

Key Financial Metrics

Price$2.29
Market Cap$183M
P/E (Forward)-1.52
Price/Book1.89
Return on Equity-93.2%
Return on Invested Capital-126.2%
Debt/Equity35.49
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-67M

Acumen Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Acumen Pharmaceuticals, Inc.’s (ABOS) StockRank?
MoatMap’s StockRank for Acumen Pharmaceuticals, Inc. (ABOS) is 27/100, with a Sell signal. It is a composite of Quality (22), Value (38), and Momentum (54) factor ranks across MoatMap’s 19,000+ stock universe.
Does Acumen Pharmaceuticals, Inc. have an economic moat?
Acumen Pharmaceuticals, Inc. (ABOS) has a Quality factor score of 22/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Acumen Pharmaceuticals, Inc. a buy, hold, or sell?
MoatMap’s current signal for Acumen Pharmaceuticals, Inc. (ABOS) is Sell, based on a StockRank of 27/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Acumen Pharmaceuticals, Inc. in?
Acumen Pharmaceuticals, Inc. (ABOS) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksABOS deep dive reportAI ChampionsHow we score stocksSense-check another stock